Tabrecta
FDA Grants Tabrecta Regular Approval for Metastatic NSCLC
The FDA granted capmatinib (Tabrecta, Novartis) regular approval for adults with metastatic NSCLC with mutations ...
AUGUST 19, 2022
Tabrecta Approved for First-Line Treatment of Extensive-Stage SCLC
The FDA approved the kinase inhibitor capmatinib (Tabrecta, Novartis) for the treatment of adults with metastatic ...
MAY 11, 2020
Load more